IN-DATE
ECP0110G: Bard EnCor Breast Biopsy Probe 10G
Sign in to add this product to your favorites!
| Price: | $117.00 EACH |
|---|---|
| Quantity: | |
| In Stock: | 3 eaches |
| Expiration: | 08-2026 |
Additional Details
BD C.R. Bard EnCor Breast Biopsy
The versatile EnCor® Breast Biopsy System delivers quality samples-even in the most difficult locations within the breast. It has been designed to provide speed and efficiency in various imaging modalities and offers a variety of options to allow you to adapt to each patient's specific needs.
Advanced Sampling Options
- Adaptability: Pre-programmed sampling patterns provide flexibility to choose pattern best suited to the lesion location
- Automated or manual sampling: Automated sampling option enables time and attention for patient support
- Size: Full- and half-sample modes provide flexibility for thin breasts and superficial lesions
- Density: Normal and dense tissue modes adjust for tissue density
Anesthetic and Marker Placement
- Pain management: Undiluted anesthetic available through the probe, as needed
- Anesthetic 360° sweep: Option to index the needle through an area of interest that allows anesthetic to be dispensed within the entire biopsy site
- Marker placement: Breast tissue markers are easily deployed through the back of the breast biopsy probe
AccessGUDID Info
- FDA Product Code: KNW
- FDA Product Code Name: INSTRUMENT, BIOPSY
- GMDN Term Code: 16835
- GMDN Term Name: Soft-tissue biopsy procedure kit, non-medicated
- GMDN Term Description: A collection of sterile devices designed to perform a non-specific soft tissue biopsy. It includes the biopsy needle used for this procedure; it does not include a pharmaceutical. This is a single-use device.
Manufacturer
C.R. Bard (a part of BD - Becton, Dickinson and Company) was a global leader in the development and manufacturing of innovative medical technologies. Known for their high-quality products, Bard specialized in solutions for vascular access, urology, oncology, and surgical specialties. Their product portfolio included catheters, biopsy devices, implantable ports, and hernia repair systems, designed to enhance patient care and procedural efficiency. As part of BD, the legacy of C.R. Bard continues to drive advancements in healthcare, delivering trusted solutions that improve outcomes for patients and providers worldwide.
